Last updated: 5 months ago
NLS Pharmaceutics Ltd. Form 6-K: December 2024 Report on FDA Pre-IND Meeting Submission
Explore NLS Pharmaceutics' December 2024 report detailing FDA Pre-IND meeting request for Type 1 Diabetes treatment. Discover key developments and strategic insights.